Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.070
Sell
RSI(14)
43.680
Neutral
STOCH(KDJ)(9,3,3)
26.966
Neutral
ATR(14)
0.170
High Vlolatility
CCI(14)
-63.877
Neutral
Williams %R
77.698
Sell
TRIX(12,20)
-0.250
Sell
StochRSI(14)
56.292
Sell
Search
Alector Inc
ALECAdd to Watchlist
2.160USD
-0.140-6.09%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
239.81MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Alector Inc
Currency: USD Updated: 2026-05-15Key Insights
Alector Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 153 out of 382 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 3.10.In the medium term, the stock price is expected to remain stable.Despite a very weak stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Alector Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Alector Inc Highlights
StrengthsRisks
Alector, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. It also develops alector brain carrier (ABC), a proprietary blood-brain barrier platform, which is applied to its next-generation product candidates and research pipeline. Its research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration. Its clinical development portfolio includes latozinemab (AL001) and AL101/GSK4527226, while its preclinical and research pipeline candidates include ADP037-ABC, ADP050-ABC, ADP056, and ADP063-ABC/ADP064-ABC. Its first product candidate, latozinemab, is a human recombinant monoclonal antibody that increases the levels of progranulin (PGRN) in the brains of FTD-GRN patients. The AL101/GSK4527226, is a human recombinant monoclonal antibody designed to elevate PGRN levels in the brain.
Growing
The company is in a growing phase, with the latest annual income totaling USD 21.05M.
Fairly Valued
The company’s latest PE is -1.82, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 89.88M shares, decreasing 26.83% quarter-over-quarter.
Held by Steven Cohen
Star Investor Steven Cohen holds 23.10K shares of this stock.
Analyst Rating
Based on
8
analysts
Hold
Current Rating
3.100
Target Price
+34.78%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-05-15The current financial score of Alector Inc is 5.63, ranking 334 out of 382 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 1.05M, representing a year-over-year decrease of 71.53%, while its net profit experienced a year-over-year decrease of 43.34%.
Score
Financials
5.05
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.89
Operational Efficiency
2.72
Growth Potential
5.37
Shareholder Returns
7.11
Alector Inc's Company Valuation
Currency: USD Updated: 2026-05-15The current valuation score of Alector Inc is 7.04, ranking 173 out of 382 in the Biotechnology & Medical Research industry. Its current P/E ratio is -1.82, which is -60.38% below the recent high of -0.72 and -234.76% above the recent low of -6.09.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 153/382
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-05-15The current earnings forecast score of Alector Inc is 6.25, ranking 332 out of 382 in the Biotechnology & Medical Research industry. The average price target is 1.50, with a high of 5.00 and a low of 0.75.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
8
analysts
Hold
Current Rating
3.100
Target Price
+34.78%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
554
Total
5
Median
6
Average
Company name
Ratings
Analysts
Alector Inc
ALEC
8
CRISPR Therapeutics AG
CRSP
27
IQVIA Holdings Inc
IQV
26
Beigene Ltd
ONC
26
argenx SE
ARGX
26
Ionis Pharmaceuticals Inc
IONS
25
1
2
3
...
111
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-05-15The current price momentum score of Alector Inc is 6.41, ranking 244 out of 382 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 2.60 and the support level at 1.86, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
2.164
Sell
MA10
2.301
Sell
MA20
2.362
Sell
MA50
2.304
Sell
MA100
2.096
Buy
MA200
2.098
Buy
Institutional Confidence
Currency: USD Updated: 2026-05-15The current institutional shareholding score of Alector Inc is 7.00, ranking 83 out of 382 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 80.95%, representing a quarter-over-quarter decrease of 17.91%. The largest institutional shareholder is James Simons, holding a total of 1.54M shares, representing 1.39% of shares outstanding, with 34.48% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Risk Assessment
Currency: USD Updated: 2026-05-15The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Alector Inc is 1.69, ranking 278 out of 382 in the Biotechnology & Medical Research industry. The company's beta value is 0.64. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. Alector Inc’s latest ESG disclosure leads the Biotechnology & Medical Research industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.
Score
Beta vs S&P 500 index
0.62
VaR
+7.62%
240-Day Maximum Drawdown
+65.66%
240-Day Volatility
+118.26%
Return
Best Daily Return
60 days
+17.67%
120 days
+17.67%
5 years
+47.26%
Worst Daily Return
60 days
-13.93%
120 days
-13.93%
5 years
-49.84%
Sharpe Ratio
60 days
+0.84
120 days
+2.00
5 years
-0.20
Risk Assessment
Maximum Drawdown
240 days
+65.66%
3 years
+89.69%
5 years
+96.84%
Return-to-Drawdown Ratio
240 days
+0.86
3 years
-0.24
5 years
-0.19
Skewness
240 days
-0.33
3 years
-0.20
5 years
-0.14
Volatility
Realised Volatility
240 days
+118.26%
5 years
+86.92%
Standardised True Range
240 days
+7.81%
5 years
+22.57%
Downside Risk-Adjusted Return
120 days
+318.08%
240 days
+318.08%
Maximum Daily Upside Volatility
60 days
+75.92%
Maximum Daily Downside Volatility
60 days
+71.40%
Liquidity
Average Turnover Rate
60 days
+0.69%
120 days
+0.94%
5 years
--
Turnover Deviation
20 days
-53.78%
60 days
-37.88%
120 days
-15.68%
Peer Comparison
Biotechnology & Medical Research
Alector Inc
ALEC
5.86 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Krystal Biotech Inc
KRYS
8.57 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
BioCryst Pharmaceuticals Inc
BCRX
8.57 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ascendis Pharma A/S
ASND
8.48 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Exelixis Inc
EXEL
8.44 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Alkermes Plc
ALKS
8.44 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
